Zanidatamab is currently being evaluated in Phase 1, Phase 2 and pivotal clinical trials as a treatment for patients with
HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor types.
Zanidatamab has been granted Breakthrough Therapy designation for biliary tract cancer from the FDA, as well as two Fast Track designations, one for previously treated or recurrent HER2-positive biliary tract cancer and another for first-line gastroesophageal adenocarcinoma in combination with standard of care chemotherapy. Zanidatamab also received Orphan Drug designations for the treatment of biliary tract, gastric and ovarian cancers in the United States and for biliary tract and gastric cancer in the European Union.
Watch the video to learn about zanidatamab's unique mechanisms of action
Click on a dot to see more information